Acticor reached the milestones triggering the second payment in the Research Agreement with its pharma partner Mediolanum
Phase 1 to start in October 2017
Paris, May 18th, 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, announced today that it has received its second payment from Mediolanum, triggered by the successful completion of relevant key milestones.
Indeed, Acticor Biotech completed the preliminary and regulatory toxicology studies on primates with ACT017, its lead candidate in the treatment of Acute Ischemic Stroke. ACT017 was found to be safe at all tested doses and did not trigger any bleeding or toxic effect.
In parallel, Acticor Biotech finalized its first GMP batch at Merck Millipore. The batch will be used in the phase I Clinical trial in 48 healthy volunteers, scheduled to start in October 2017 and to end in January 2018.
Acticor Biotech’s CEO Gilles Avenard stated: “We have made excellent progress in our development program. Our near-term objective is now to perform the clinical phase I to confirm the safety profile of our lead candidate. In parallel, we have developed a clear clinical development pathway and the first phase II study is estimated to start end Q2 2018. We are convinced that our innovative therapeutic approach combined with the safety profile of ACT017 is well positioned to trigger a paradigm shift in the management of Acute Ischemic Stroke.”
About Ischemic stroke
Today stroke is the second cause of death in industrialized countries (6 million deaths worldwide), the second cause of dementia after Alzheimer’s disease, and the leading cause of acquired disability in adults. In Europe and in the US, the annual incidence of stroke is estimated at more than 1,500,000 cases. This devastating disease is responsible for health and economic needs that current treatments do not address. In fact, less than 15% of patients can be treated with thrombolysis and/or thrombectomy. Therefore, it is urgent to promote new therapeutic, innovative, safe and effective strategies for the treatment of acute ischemic stroke. New antiplatelet drug represents a unique opportunity to increase the efficacy of acute stroke therapies with reduced adverse events.
About ACT017, the Therapeutic Candidate
Acticor is developing ACT017, a humanized Antibody Fragment (Fab). The therapeutic candidate is directed against a novel target of major interest, platelet glycoprotein VI (GPVI), of which it inhibits its action. Evidence of antithrombotic efficacy of ACT017 and safety of inhibition of GPVI have been established both ex vivo and in vivo. The target is involved in the growth of the thrombus, but not in physiological haemostasis. This limits the bleeding risk associated with its inhibition.
About Acticor Biotech
Acticor Biotech is a bio-pharmaceutical company, spin-off of Inserm (U1148 – Bichat Hospital, Paris, France) founded late 2013, dedicated to developing an innovative treatment for acute ischemic stroke, i.e. a Fab directed against platelet glycoprotein GPVI. Acticor Biotech is built upon the expertise of and the results of researches conducted by, the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Professor Philippe Billiald at Paris-Sud University.
For more information, go to: https://acticor-biotech.com/
About Mediolanum Farmaceutici
Mediolanum Farmaceutici is a privately owned pharmaceutical Group, headquartered in Milan and founded in 1972 by Mr. Rinaldo Del Bono. In its 45 years’ history, Mediolanum has submitted applications for 93 inventions, obtaining nearly 700 patents, and has fully developed 4 new pharmaceutical products. In the 2000s, the CEO Alessandro Del Bono launched a new phase of growth, acquiring Istituto Gentili and Neopharmed, now merged into ‘NeopharmedGentili’. Current core business is focused on cardiovascular, osteoporosis and diabetes. The Group – that also includes Cristalfarma, a phytotherapy food supplement company – and the French subsidiary Laboratoires Leurquin Mediolanum, employs about 500 people with an aggregated turnover of about 200 million Euros.
For more information, go to: http://www.mediolanum-farma.it/en/index.html
Chief Executive Officer
Media – NewCap
+33(0) 1 44 71 00 12 / +33(0) 6 88 20 35 59
+33(0)1 44 71 20 41 / +33(0) 6 58 14 84 66
Read next in 'Press Releases'
- Acticor Biotech has selected its Contract Research Organisation to manage Clinical Study Phase I
- Acticor Biotech Secures €1,5M new funding from CapDecisif Management
- Stroke company Acticor Biotech and Mediolanum announce a Research Collaboration Agreement
- €1.4 million capital increase by Acticor Biotech
- Acticor Biotech selects Catalent GPEx® Cell Line Development Technology to develop ACT017